Invasive adenovirus (AdV) infections are associated with high morbidity and mortality in allogeneic stem cell transplant recipients. We observed that molecular detection of the virus in stool specimens commonly precedes AdV viremia, suggesting that intestinal infections may represent a common source of virus dissemination. To address this notion, we have investigated 153 consecutive allogeneic transplantations in 138 pediatric patients by quantitative monitoring of AdV in stool specimens and peripheral blood by a pan-adenovirus real-time (RQ)-PCR approach. AdV was detectable in serial stool specimens in all cases of AdV viremia during the post-transplant course (Po0.0001). The incidence of AdV viremia in individuals with peak virus levels in stool specimens above 1 Â 10E6 copies per gram (n ¼ 22) was 73% vs 0% in patients with AdV levels in stool specimens below this threshold (n ¼ 29; Po0.0001). Serial measurement of AdV levels in stool specimens by RQ-PCR permitted early diagnosis of impending invasive infection with a sensitivity and specificity of 100% (95% confidence interval (CI) 96-100%) and 83% (95% CI 67-92%), respectively. The median time span between detection of AdV loads in stool specimens above 1 Â 10E6 copies per gram and first observation of viremia was 11 days (range 0-192). Quantitative monitoring of the AdV load in stool specimens therefore provides a rationale for early initiation of antiviral treatment with the aim of preventing progression to life-threatening invasive infection.
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Invasive adenovirus (AdV) infections are associated with high morbidity and mortality in allogeneic stem cell transplant recipients. We observed that molecular detection of the virus in stool specimens commonly precedes AdV viremia, suggesting that intestinal infections may represent a common source of virus dissemination. To address this notion, we have investigated 153 consecutive allogeneic transplantations in 138 pediatric patients by quantitative monitoring of AdV in stool specimens and peripheral blood by a pan-adenovirus real-time (RQ)-PCR approach. AdV was detectable in serial stool specimens in all cases of AdV viremia during the post-transplant course (Po0.0001). The incidence of AdV viremia in individuals with peak virus levels in stool specimens above 1 Â 10E6 copies per gram (n ¼ 22) was 73% vs 0% in patients with AdV levels in stool specimens below this threshold (n ¼ 29; Po0.0001). Serial measurement of AdV levels in stool specimens by RQ-PCR permitted early diagnosis of impending invasive infection with a sensitivity and specificity of 100% (95% confidence interval (CI) 96-100%) and 83% (95% CI 67-92%), respectively. The median time span between detection of AdV loads in stool specimens above 1 Â 10E6 copies per gram and first observation of viremia was 11 days (range 0-192). Quantitative monitoring of the AdV load in stool specimens therefore provides a rationale for early initiation of antiviral treatment
Introduction
Adenoviruses (AdVs) are pathogens causing serious infections in immunosuppressed patients, particularly in allogeneic bone marrow transplant recipients. [1] [2] [3] [4] [5] [6] [7] To date, more than 50 human AdV serotypes showing different tissue tropism have been identified, and the number of new putative serotypes is increasing. They have been divided into six major subgroups (subgenera or species A-F) on the basis of the oncogenic, hemagglutinating, morphological and DNA sequence properties. [8] [9] [10] [11] [12] Infections can cause localized disease such as enteritis, upper respiratory tract infection, encephalitis or cystitis. [13] [14] [15] However, AdV infections in immunocompromised patients tend to become invasive, and disseminated disease is associated with very high mortality. 3, 11, 16 We have established a pan-adenovirus real-time PCR assay and demonstrated that AdV detection in peripheral blood (PB) of patients during the post-transplant period is associated with very high morbidity and mortality. 1 Although molecular detection of viremia was shown to precede the onset of clinical symptoms of disseminated viral disease, preemptive antiviral treatment with virustatic agents such as cidofovir, ribavirin or foscarnet administered at first detection of the virus in PB failed to prevent lethal outcome of AdV disease in most instances. 1, 11, 17, 18 It has been shown that the adoptive transfer of donor-derived AdV-specific T-lymphocytes may provide an attractive treatment option in patients with invasive AdV infection, but the favorable outcome observed upon in vivo expansion of the transferred T cells appeared to be related to the early onset of adoptive T-cell transfer during the course of infection. 19, 20 These observations suggested that timely initiation of antiviral treatment, possibly before the occurrence of invasive infection, might be beneficial.
The findings of our earlier study revealed that virtually all patients who experienced systemic AdV infection had the virus detectable in serial stool specimens, with or without clinical symptoms of enteritis, before the onset of viremia, 1 indicating that the intestinal tract may be a common source of virus dissemination. Based on this concept, it was intriguing to consider the notion that initiation of antiviral therapy at the time of intestinal infection could prevent invasive infection by controlling proliferation of the virus at a localized stage. The presence of AdV in stool specimens is, however, a very common finding in transplant recipients, and in most instances the virus is cleared without antiviral treatment. Hence, administration of antiviral therapy in all patients with AdV detectable in serial stool specimens would result in overtreatment in a great proportion of individuals. This concept therefore appears questionable, particularly in view of the toxicity and the cost of cidofovir, which is currently regarded as the most effective antiadenoviral agent. 21 Hence, we were interested in determining whether a subset of patients positive for AdV in stool specimens could be identified who have a particularly high risk of virus dissemination, and who could therefore benefit from an early initiation of treatment. To evaluate risk factors for viral dissemination during the course of intestinal AdV infection, we performed the present prospective study in a series of pediatric patients who underwent allogeneic stem cell transplantation (SCT) at our center.
Materials and methods

Patient characteristics
Over a period of 6 years (October 1999 to September 2005), 170 allogeneic SCTs were performed in 138 pediatric patients at the St Anna Children's Hospital, Vienna, Austria. Fifteen patients underwent a second SCT for relapse or late graft rejection. For 17 patients who received a second graft following non-engraftment or early graft rejection, the first SCT was excluded from the analysis. Hence, 153 SCTs were included in the study. Written informed consent was obtained from each patient and/or the parents, and the transplantation protocol was approved by the institutional review board of St Anna Children's Hospital. Patient characteristics and transplantation modalities are summarized in Table 1 . Myeloablative conditioning regimens consisted of total body irradiation with 12 Gy or busulfan 16 mg/kg and cyclophosphamide with or without etoposide. Patients with nonmalignant disorders, patients undergoing second SCT and patients with severe pre-transplant morbidity received a fludarabine/melphalan-based reducedintensity conditioning regimen. Ex vivo T-cell depletion by CD34
þ selection was performed in SCTs from mismatched unrelated or haploidentical family donors. In patients with severe combined immunodeficiency, severe aplastic anemia and mismatched or unrelated donors, in vivo T-cell depletion was performed with ATG or Campath. Graft-vs-host disease (GvHD) prophylaxis consisted of cyclosporine A and, in recipients of non-T-cell-depleted grafts from unrelated donors, an additional short methotrexate course. In patients who received reduced-intensity conditioning regimens, mycophenolate mofetil was given in addition. All patients were nursed in laminar airflow units. The observation time within the entire cohort of surviving patients was 2 years or more.
Antiviral prophylaxis and treatment
Antiviral prophylaxis consisted of acyclovir 30 mg/kg per day intravenously from day À7 until day þ 28 for HSV-IgG-positive patients and gancyclovir 10 mg/kg for CMV-IgG-positive patients with CMV-IgG-negative donors. Patients with a positive PCR test in PB for cytomegalovirus (CMV) or AdV were regarded as eligible for preemptive antiviral treatment, regardless of the viral load. Treatment was initiated upon availability of PCR results, generally within 48-72 h after sampling. Patients with CMV-DNAemia received primary preemptive therapy with gancyclovir and, in case of persistent DNAemia, secondary preemptive treatment with cidofovir, until two consecutive negative results were obtained. Patients with adenovirusDNAemia received preemptive treatment with cidofovir and/or ribavirin until resolution of DNAemia.
Since September 2002, five patients with adenovirus-DNAemia who did not respond to antiviral chemotherapy, and had no detectable AdV-specific T cells, were offered treatment by donor-derived AdV-specific T cells. 19 
Sample collection for virus testing
Routine virus screening for CMV and Epstein-Barr (EBV) virus was performed by real-time PCR in PB, and for AdV in stool and PB. 22, 23 Whenever possible, patients were tested before conditioning, and prospective virus screening was performed in all patients at 7-day intervals until day þ 100 after transplant. After day þ 100, tests were carried out only in cases of clinically suspected or PCR-documented viral infection. Screening for other viruses was performed on clinical suspicion only.
Isolation of viral DNA
DNA extraction from PB, serum or isolated leukocytes for detection of intracellular virus particles was performed using the QIAamp DNA Mini Kit. Isolation of virus DNA from stool specimens was performed using the QIAamp DNA Stool Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's recommendations.
Quantitative PCR analysis of AdV
Six different primer/probe systems were used for detection of the individual AdV species (subgenera) A-F as described previously. 1, 22 PCR reactions were set up in a total volume of 25 ml including 6 ml template DNA and 12.5 ml TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA, USA). The concentration of primers and FAM-labeled probe for each detection system was as described. 1, 24 Amplifications were carried out using the ABI Prism 7700 or 7900 Sequence Detectors (Applied Biosystems, Foster City, CA, USA) for 50 cycles. After an initial denaturation step for 10 min at 95 1C, each cycle consisted of denaturation for 15 s at 95 1C, and annealing and primer extension for 60 s at 60 1C.
Strict precautions were undertaken to prevent contamination of PCR reactions with exogenous products as described. 25 A dUTP glycosylase step was performed before each PCR reaction. Each DNA sample was analyzed in duplicates, and multiple negative controls were included in each assay.
For quantitative analysis of virus load, real-time TaqMan PCR was performed using the equipment indicated above. External standard curves for each AdV species were established by making serial dilutions of quantified virus preparations derived from reference strains. For assessment of virus copies per cell, a single copy gene (b2 microglobulin) was quantified in parallel Abbreviations: PBSC, peripheral blood stem cell; SCT, stem cell transplantation.
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by real-time PCR. 26 When investigating plasma or serum specimens from PB, quantitative results were expressed as the number of virus copies per ml. In stool samples, the virus copies were calculated per gram material, and intracellular virus copies were indicated per 10 6 cells. The sensitivity of the PCR assays permitted reliable detection of 2 Â 10 2 virus particles per ml of the medium investigated. For reproducible quantification of virus load, however, the presence of X10 3 particles per ml was necessary. When analyzing cell material, sensitivity of the assays permitted detection and quantification of virus copies at a level of 10 particles per 10 6 cells.
Monitoring of leukocyte subsets
The number and proliferation kinetics of leukocyte subsets including granulocytes, monocytes, natural killer cells, T cells, B cells and stem cells were analyzed in post-transplant PB samples by four-color quantitative fluorescence-activated cell sorting (FACS) analysis on the FACSCalibur (BD Biosciences, San Jose, CA, USA) at 3-to 7-day intervals, as described previously.
27
Definitions
Localized and disseminated AdV infections, as well as definite and probable AdV disease, were defined as described, with minor modifications reflecting the use of PCR detection assays. 28, 29 In stool specimens monitored after allogeneic SCT, reproducible presence of AdV at levels detectable and quantifiable by RQ-PCR together with enteritis, in the absence of other infections or GvHD, was regarded as intestinal disease. In asymptomatic patients, AdV in stool specimens at levels detectable by PCR was regarded as virus shedding only. Viremia was defined by positive AdV-PCR tests from PB. Probable AdV disease was defined as the presence of two or more positive PCR assays in samples from PB, in association with compatible symptoms, without other identifiable causes. Disseminated AdV disease was defined as multiple organ involvement (for example, hepatitis, encephalitis, retinitis) in the presence of two or more AdV-positive PCR assays in PB and other sites tested (for example, cerebrospinal fluid, bronchoalveolar lavage, respiratory secretions, urine), in the absence of other identifiable causes. All patients with fever, unexplained symptoms or laboratory test abnormalities were carefully tested for infections and GvHD. AdV-associated death was defined as multiple organ failure in the presence of increasing or persisting adenovirus load in PB, in association with AdV detection from multiple other sites.
Statistical analysis
Cumulative incidences were calculated to assess the time from SCT to viremia and disseminated disease. Cox regression analysis was used to study the impact of different potential prognostic factors on the incidence of viremia and disseminated disease. The risk factors analyzed in addition to AdV positivity and viral load in stool specimens included underlying disease, donor type, GvHD of all grades, T-cell depletion in vivo and ex vivo, T-cell reconstitution and presence of other virus infections. Patients without any event were censored at the time of their last follow-up evaluation or death. Explanatory variables whose values may change over time, such as lymphocyte reconstitution, viral co-infection, acute GvHD, AdV positivity and load, were included as time-dependent covariates in the evaluation. For the comparison of AdV positivity, penalized likelihood ratio tests were used, because all events were in the AdV-positive group (monotone likelihood). In multivariate analysis, the impact of AdV detectability in stool specimens (positive vs negative and load 410E6 per gram) was adjusted for donor type, disease and acute GvHD (aGvHD). All the indicated P-values are two sided. P-values p0.05 were considered significant, and P-values p0.001 as highly significant. Relative hazard rates (relative risk) and their 95% confidence interval (CI) are indicated in addition to P-values.
Differences between patient groups including (1) AdVnegative patients; (2) patients positive for AdV in stool specimens, but negative in PB; (3) patients positive for AdV in PB and (4) patients with disseminated AdV disease were analyzed using w 2 -test. For analysis of small cohorts, Fisher's exact test was used. The correlation between AdV infection and the risk of mortality was determined by Cox regression analysis with timedependent covariates.
Results
Adenovirus monitoring in stool specimens after allogeneic stem cell transplantation
In a series of 153 consecutive transplants, molecular screening for AdVs in serial stool specimens during the post-transplant period revealed positive results in 51 cases (33%). Genotype analysis was available in 45 of 51 (88%) of the AdV-positive patients. There was a strong predominance of the subgenus C (76%), whereas other species were far less commonly observed: A (11%), D (7%) B (4%) and F (2%). In three patients, concomitant presence of two AdV species or serotypes was detected. Serotyping was possible in 37 of 51 (73%) of the AdVpositive patients and revealed the following distribution: C02 (43%), C01 (38%), A12 (8%), A31 (5%), B3 (2%), B16 (2%) and D19 (2%).
In most instances (n ¼ 50), intestinal shedding was documented during the first 6 months after transplant, whereas later onset of infection was observed in one child only. Viral load in stool specimens ranged from 1 Â 10E2 to 1 Â 10E11 copies per gram or, in case of liquid excretions, per ml stool.
Twenty-nine patients had maximum virus levels of p1 Â 10E6 copies (Table 2b) , and only one of these patients had signs of acute intestinal infection. In patients with low AdV levels, the kinetics of virus proliferation was generally slow or the virus load remained at a low level until spontaneous clearance. In 22 cases, the AdV load in serial stool specimens reached levels higher than 1 Â 10E6 copies per gram or ml, ranging from 4 Â 10E6 to 1 Â 10E11 (Table 2a) . In these patients, rapid AdV proliferation was mostly observed in serial stool samples, revealing an increase in viral load by several logs within a period of 1-2 weeks. In total, three patients showed clinical signs of enteritis in the absence of other identifiable infections or GvHD, but the presence or absence of probable intestinal disease did not correlate with the viral load.
Association AdV load in stool with viremia
Overall, AdV was detectable in PB in 16 of 153 (10.5%) cases. With the exception of one patient, in whom AdV was first detected on day þ 224, the onset of viremia occurred within the first 6 months after transplant in all children, with a median on day þ 49 (range day þ 11 to þ 153) (Figure 1 ). Viremia has occurred in 11 of 40 patients who had infections by serotypes of species C, and in 5 of 6 patients who carried serotypes of species A. Viremia has not been observed in patients without preceding adrenoleukodystrophy; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CGD, chronic granulomatous disease; CML, chronic myeloid leukemia; CVID, common variable immunodeficiency; DEA, dyserythropoietic anemia; Diss., disseminated; FA, Fanconi's anemia; HLH, hemophagocytic lymphohistiocytosis; LCH, Langerhans cell histiocytosis; Max. AdV load, maximal AdV load in stool indicated as virus copies per gram; MDS, myelodysplastic syndrome; mmFD, mismatched family donor; mmUD, mismatched unrelated donor; MPS, mucopolysaccharidosis; MSD, matched sibling donor; MUD, matched unrelated donor; NA*, AdV-negative in stool until day 100 post-transplant with no stool specimens available thereafter; ND, not determined; NHL, nonHodgkin's lymphoma; PBSC, peripheral blood stem cells; PCP, Pneumocystis (jiroveci) carinii pneumonia; SAA, severe aplastic anemia; SCD, sickle cell disease; SCID, severe combined immunodeficiency; TA, thalassemia; TRM, transplant-related mortality; viremia-day, first observation of viremia; WG, Wegener's granulomatosis; XLP, x-linked lymphoproliferation.
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Table 2b
Characteristics of patients with high and low viral load (AdV-positive patients with viral load Table 2a footnote. Identification of the AdV species present was possible in virtually all patients, while identification of the serotype could not be performed in all instances.
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positive stool results, with the exception of one patient in whom the first detection of viremia was as early as on day þ 11 and coincided with the first AdV positivity in stool specimens. Among patients who were AdV negative in serial stool specimens (n ¼ 102) or who showed AdV levels not exceeding 1 Â 10E6 copies per gram (n ¼ 29), there was no occurrence of viremia during the entire observation period (Tables 2b and 3 ). The overall incidence of viremia in patients with intestinal AdV shedding showing copy numbers above 1 Â 10E6 copies per gram (range 4 Â 10E6 to 1 Â 10E11) was 73% (16 of 22) ( Table 3 ). Serial measurement of AdV levels in stool specimens by RQ-PCR permitted early diagnosis of impending invasive infection with a sensitivity of 100% (95% CI 96-100%) and a specificity of 83% (95% CI 67-92%), reflecting a negative predictive value of 100% (95% CI 88-100%) and a positive predictive value of 73% (95% CI 52-87%).
In patients who experienced viremia, peak AdV levels in stool specimens were in a range between 2 Â 10E7 and 1 Â 10E11 copies per gram (median 1 Â 10E9), and the first appearance of the virus in PB was observed when virus copy numbers in stool specimens reached 3 Â 10E6 to 6 Â 10E9 copies per gram (median 1 Â 10E8). The median time span between the detection of AdV load in stool specimens above 1 Â 10E6 copies per gram and first appearance of the virus in PB was 11 days (range 0-192 days) (Table 2a ). Only 6 of the 22 patients with peak AdV levels in serial stool specimens above 1 Â 10E6 copies per gram did not experience viremia during the post-transplant period. Most of these patients also showed rapidly increasing virus copy numbers in stool specimens, but the peak levels, which ranged from 4 Â 10E6 to 5 Â 10E7 copies per gram (median 1 Â 10E7), were considerably lower in comparison with individuals who experienced viremia during the post-transplant course.
Of the 16 patients with AdV viremia, eight experienced disseminated disease that was lethal in all instances, despite the initiation of virustatic therapy with cidofovir with or without ribavirin upon detection of the virus in PB. In these patients, AdVs of species C and A were detected in five and three cases, respectively. The median time span between the first detection of viremia and onset of disseminated disease was 10.5 days (range 0-59 days) (Table 2a) . AdV-positive patients with copy numbers above or below 1 Â 10E6 copies per gram, and the time from the detection of high AdV loads in stool (41 Â 10E6 copies per gram) to the occurrence of viremia and disseminated disease are summarized in Table 2a and b.
Risk factors of invasive adenovirus infection
In univariate analysis, the presence of intestinal infection with peak virus levels above 1 Â 10E6 copies per gram was a highly significant risk factor for the occurrence of viremia (Po0.0001). Conversely, absence of AdV positivity in serial stool specimens or presence of the virus at low levels, below the threshold of 1 Â 10E6 copies per gram, predicted a very low risk of adenoviremia (Po0.0001; Tables 3 and 4) . On multivariate analysis, AdV positivity and high AdV virus levels in stool specimens (410E6 copies per gram) remained highly significant as risk factors for viremia and disseminated disease (Pp0.001).
In addition, the following parameters were assessed for potential association with the risk of viremia and disseminated AdV disease: underlying disease, donor type, conditioning regimen, T-cell depletion in vivo or ex vivo, aGvHD of all grades, lymphocyte reconstitution (absolute lymphocyte count and lymphocyte subsets) and concomitant infection with other viruses. Lymphocyte reconstitution was assessed by FACS analysis, and reconstitution of the T-cell subset was defined as a CD3 þ cell count above 300 cells per ml PB within 30 days after first detection of AdV in stool specimens. Besides AdV positivity and virus load in stool specimens, acute GvHD grade III-IV and a lymphocyte count below 300 CD3 þ cells per ml in PB were the only variables associated with a significantly increased risk of AdV viremia and/or disseminated disease (Table 4) .
Transplant-related mortality
Within the entire cohort of 138 patients studied, 102 (74%) are alive and well after an observation period of more than 2 years. Causes of death included relapse in 7%, and transplant-related complications in 19%. Transplant-related mortality in children showing high AdV loads in stool (41 Â 10E6 copies per gram) or AdV viremia was significantly higher than in patients who had AdV levels in stool specimens below the threshold of 1 Â 10E6 copies per gram or those who were completely AdV negative (Figure 2 ).
In patients with low AdV loads in stool specimens (p1 Â 10E6 copies per gram), the virus was cleared in all instances, without the need for AdV-directed antiviral therapy, and the transplantrelated mortality in this subset of patients was similar to that of AdV-negative individuals. Figure 1 Time to viremia and to disseminated disease in patients with high adenovirus (AdV) load in stool specimens. The 100-day cumulative incidence of viremia (dashed line) and disseminated disease (solid line) was 59% ( ± 10%) and 36% ( ± 10%), respectively, in patients with AdV positivity in stool specimens 410E6 viral copies per gram. All cases of disseminated disease were observed before day 100 after transplant. Abbreviations: AdV, adenovirus; pts., patients.
Patients who are AdV-positive in stool have a significantly higher risk of developing viremia than AdV-negative patients (Po0.0001). However, the increased risk of developing viremia is clearly restricted to individuals with a high viral load (410E6) (Po0.0001).
Antiviral treatment and outcome
All eight patients who had AdV-related disseminated disease died despite the administration of cidofovir with or without ribavirin upon first appearance of the virus in PB. Two of the patients (UPN 458 and 534) were offered adoptive transfer of AdV-specific T cells, which became available relatively late in the course of infection, 65 and 95 days after the onset of viremia. Three other patients (UPN 490, 502 and 560) also received AdV-specific T cells from the original stem cell donor at 12, 5 and 37 days after first observation of viremia, respectively, and none of them experienced disseminated disease.
Discussion
Disseminated AdV disease after allogeneic SCT is a potentially life-threatening event occurring in 2-6% of transplanted children, contributing substantially to transplant-related mortality. 1, 4, 7, 30 Although AdV disease usually occurs between 2 and 3 months after transplant, screening studies in the pediatric setting showed that the median time point of the first AdV detection in stool specimens, urine or PB varies between days þ 12 and þ 44, which might open a window for early initiation of therapy. 1, 4, 5 Lethal AdV disease seems to occur particularly during the first 100 days after transplantation, regardless of AdV-directed antiviral therapy. In line with our earlier observations, patients showing AdV viremia before day 100 developed life-threatening disseminated disease in more than 60% of instances despite antiadenoviral treatment, whereas later onset of viremia did not seem to be associated with disseminated AdV disease. 1 We and others have therefore strongly recommended weekly AdV surveillance by PCR in PB and at other sites of potential relevance including stool specimens, urine and throat AdV positive AdV load >10E6 Figure 2 Intestinal adenovirus (AdV) infection and mortality. The correlation between AdV infection and mortality (y axis) is shown for different groups of patients: (1) the entire cohort studied, (2) patients positive for AdV in stool specimens at any level, (3) the subset of patients with high viral load (410E6 viral copies per gram) and (4) patients who developed viremia. Although the difference between all AdV-positive individuals and the entire cohort of patients investigated was not statistically significant, patients with high viral load in stool specimens had a significantly higher risk of mortality in comparison with the previous two groups (P ¼ 0.005; HR ¼ 2.6). In patients who developed viremia, the risk of mortality in comparison with all other groups was significantly increased (Po0.001; HR ¼ 4.9). Lymphocyte reconstitution CD3+ o300 cells per ml
T-cell depletion In vivo vs none during the first 3-4 months after transplant in all patients. 1, 29 Long-term surveillance has been recommended for all patients with severe GvHD and for severely immunosuppressed patients with in vivo and/or ex vivo T-cell depletion. 29 In patients with viremia, reduction of immunosuppression and initiation of preemptive treatment with cidofovir has become the standard of care in many centers. 29, [31] [32] [33] However, the observations made at our and other institutions indicate that initiation of antiviral treatment at the time of first detection of viremia may not prevent progression to severe AdV disease in many instances, and that earlier initiation of preemptive treatment could therefore be beneficial. 1, 7, 11, 21, 30, [33] [34] [35] [36] Adenoviruses are known to persist in epithelial cells and lymphoid tissue, and AdV infections occurring during the posttransplant period appear to result from virus reactivation in most instances. Our observations revealed that virtually all patients who experienced systemic AdV infection had the virus detectable in serial stool specimens, with or without clinical symptoms of enteritis, before the onset of viremia. 1 These findings suggest that the intestinal tract may be the primary site of AdV reactivation, at least in pediatric transplant recipients. 1, 4, [37] [38] [39] [40] It appears intriguing, therefore, to consider the initiation of antiviral therapy at the time of intestinal infection, with the aim to prevent invasive infection by controlling proliferation of the virus at a localized stage. It is important to point out, however, that the presence of AdV in stool specimens is a very common finding during the post-transplant period and most of these patients remain asymptomatic and clear the virus without the use of antiviral treatment. 41 In view of the considerable nephrotoxicity of cidofovir and the high cost of treatment, preemptive therapy for all patients with AdV-positive stool samples is not generally recommended. 1, 2, 4, 21, 31, 33, 42 Prospective quantitative PCR screening in stool specimens and PB in this study of 153 pediatric allogeneic SCTs revealed that virtually all patients with AdV viremia showed rising virus copy numbers in serial stool specimens exceeding the threshold of 10E6 viral particles per gram before first appearance of the virus in PB (Po0.0001). The only exception in this series was a patient with onset of viremia very early after transplant (day þ 11) in whom detection of AdV in PB coincided with first observation of the virus in stool specimens. The critical threshold of 10E6 viral particles per gram stool preceded the onset of viremia by a week or more in the majority of instances. Our results suggest that quantitative monitoring of AdV load in stool specimens facilitates reliable prediction of imminent viremia and disseminated disease. The proliferation dynamics and the load of AdV particles in stool specimens may therefore serve as a rational parameter for early initiation of treatment (Supplementary Figure 1) . It is conceivable that the initiation of antiviral therapy at this early stage may inhibit or slow down proliferation of the virus until recovery of the immune system permits control of the infection. This approach may be instrumental in preventing life-threatening disseminated AdV disease in individuals at high risk, while limiting the rate of overtreatment in patients after allogeneic SCT.
